-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Gfx/E55RGselfAib/3HX8vlV6y8skhRPGBVbl28iIzfOH0kMMRMR0pmuoVh1WddU t6SxIemSguBlQ8DN9sYziQ== 0000051396-98-000028.txt : 19980424 0000051396-98-000028.hdr.sgml : 19980424 ACCESSION NUMBER: 0000051396-98-000028 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19980421 ITEM INFORMATION: FILED AS OF DATE: 19980422 SROS: CSX SROS: NYSE SROS: PCX FILER: COMPANY DATA: COMPANY CONFORMED NAME: MALLINCKRODT INC /MO CENTRAL INDEX KEY: 0000051396 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 361263901 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-00483 FILM NUMBER: 98598783 BUSINESS ADDRESS: STREET 1: 675 MCDONNELL BLVD STREET 2: PO BOX 5840 CITY: ST LOUIS STATE: MO ZIP: 63134 BUSINESS PHONE: 3146542000 MAIL ADDRESS: STREET 1: 7733 FORSYTH BLVD CITY: ST LOUIS STATE: MO ZIP: 63105-1820 FORMER COMPANY: FORMER CONFORMED NAME: MALLINCKRODT INC /MO DATE OF NAME CHANGE: 19970625 FORMER COMPANY: FORMER CONFORMED NAME: MALLINCKRODT GROUP INC DATE OF NAME CHANGE: 19940322 FORMER COMPANY: FORMER CONFORMED NAME: IMCERA GROUP INC DATE OF NAME CHANGE: 19920703 8-K 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 21, 1998 Mallinckrodt Inc. (Exact name of registrant as specified in its charter) New York 1-483 36-1263901 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 675 McDonnell Boulevard, St. Louis, MO 63134 (Address of principal executive offices) (ZIP Code) Registrant's telephone number, (314) 654-2000 including area code Item 5. Other Events A press release was issued April 21, 1998. The relevant portion of the text of that release was as follows: (*) Indicates registered trademark. MALLINCKRODT PROVIDES NEAR-TERM OUTLOOK IN CONJUNCTION WITH THIRD QUARTER EARNINGS REPORT ST. LOUIS, Mo., April 21, 1998 - During a conference call earlier today to discuss third quarter results with analysts, Mallinckrodt Inc. (NYSE:MKG) Chief Financial Officer Michael A. Rocca commented on the near-term outlook for fiscal years 1998 and 1999. While stating that earnings for all of fiscal 1998, ending June 30, will be in line with overall market expectations, he indicated that certain factors will impact fiscal 1999 earnings growth. The three factors noted by Rocca that will have an influence on fiscal 1999 are a decrease in ongoing earnings, resulting from the divestiture of the company's specialty industrial chemical businesses; continued price deterioration in the X-ray contrast business, resulting in reduced imaging business results; and the delay the company experienced in marketing OPTISON(*), due to later- than-planned regulatory approval, which is pushing the cardiac ultrasound contrast imaging agent's ramp-up and earnings contribution out by about a half year. While the company's revised long-range forecast and fiscal 1999 operating plan, currently being prepared under the normal planning process, will not be complete for the next several months, it is likely that FY99 earnings per share will be below $2.60, which is at the lower end of the range mentioned by investment analysts in their previous projections. Based in St. Louis, Missouri, and operating in more than 100 countries globally, Mallinckrodt had fiscal 1997 net sales of $1.9 billion. The Mallinckrodt web site address is(www.mallinckrodt.com). # # # This news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations; actual results may differ materially. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and continued pressure on prices realized by the company for its products; constraints on supplies of raw materials used in manufacturing certain of the company's products; capacity constraints limiting the production of certain products; difficulties or delays in the development, production, testing, and marketing of products; difficulties or delays in receiving required governmental or regulatory approvals; market acceptance issues, including the failure of products to generate anticipated sales levels; difficulties in rationalizing acquired businesses and in realizing related cost savings and other benefits; the effects of and changes in trade, monetary and fiscal policies, laws and regulations; foreign exchange rates and fluctuations in those rates; the costs and effects of legal and administrative proceedings, including environmental proceedings and patent disputes involving the company; and the risk factors reported from time to time in the company's SEC reports. Mallinckrodt Inc. ROGER A. KELLER Vice President, Secretary and General Counsel DATE: April 22, 1998 -----END PRIVACY-ENHANCED MESSAGE-----